Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENX-104
- Development stage
- Phase 1
- Lead developer
- Engrail Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ENX-104 is an investigational small molecule being developed by Engrail Therapeutics for the treatment of major depressive disorder with anhedonia. Clinical studies are evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and its ability to occupy D2/D3 dopamine receptors.
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on ENX-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENX-104.